Macy's Inc vs Smith & Nephew plc — how do they compare? Macy's Inc trades at $23.61 (market cap $6.13B), while Smith & Nephew plc trades at $30.14 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 2.1× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.29%). Which is the better fit depends on your goals.
| M | SNN | |
|---|---|---|
Market Cap | $6.13B | $12.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.96 | $38.70 |
52-Week Low | $11.90 | $28.73 |
Enterprise Value | $9.95B | $15.41B |
Dividend Yield | 3.29% | 2.57% |
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $23.39, down 1.22% on the day, with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. Positive sentiment is driven by the 'Bold New Chapter' turnaround strategy, with Berkshire Hathaway's new 3.04 million-share position adding institutional confidence.
The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 6% upside potential. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from store closures and macroeconomic sensitivity. The stock presents value characteristics with growth catalysts from operational improvements.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →